Smith & Nephew plc: 2011 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Smith & Nephew plc (UK-incorporated, NYSE-listed via ADSs)
Reporting Period: Fiscal year ended December 31, 2011
Business Overview: A global medical technology leader in Orthopaedics (reconstruction and trauma), Endoscopy (sports medicine), and Advanced Wound Management. The company operates in over 90 countries with approximately 11,000 employees.
Strategic Shift: In August 2011, the company announced a new strategic framework, consolidating Orthopaedics and Endoscopy into the "Advanced Surgical Devices" division (effective 2012 reporting) and focusing on Emerging Markets (China, India, Brazil, Russia).
Key Financial Metrics (2011 vs. 2010)
| Metric | 2011 ($ million) | 2010 ($ million) | Change |
|---|---|---|---|
| Revenue | 4,270 | 3,962 | +8% (4% underlying) |
| Operating Profit | 862 | 920 | -6% |
| Trading Profit (Non-GAAP) | 961 | 969 | -1% |
| Profit Before Tax | 848 | 895 | -5% |
| Attributable Profit | 582 | 615 | -5% |
| Adjusted Attributable Profit (Non-GAAP) | 664 | 654 | +2% |
| Basic EPS | 65.3p | 69.3p | -6% |
| Adjusted EPS (EPSA) | 74.5p | 73.6p | +1% |
| Cash Generated from Operations | 1,135 | 1,111 | +2% |
| Trading Cash Flow (Non-GAAP) | 838 | 825 | +2% |
| Net Debt | 138 | 492 | -72% reduction |
Material Changes and Segment Performance
- Revenue Growth: Driven by 4% underlying growth and 4% favorable currency translation.
- Orthopaedics: Revenue $2,312m (+5%). Underlying growth of 2%. Knee products (VERILAST) drove growth; hip sales declined slightly.
- Endoscopy: Revenue $939m (+10%). Underlying growth of 6%. Strong performance in sports medicine repair.
- Advanced Wound Management: Revenue $1,019m (+12%). Underlying growth of 7%. First year exceeding $1 billion revenue.
- Profitability Pressure: Operating profit declined due to a $23m legal provision (FCPA investigation), $40m in restructuring costs, and pricing pressures in established markets. Trading profit margin decreased to 22.5% from 24.5%.
- Balance Sheet: Significant deleveraging occurred. Long-term borrowings dropped from $642m to $16m as a major loan was reclassified to current liabilities. Net debt reduced to $138m.
- Assets Held for Sale: $125m in assets (Clinical Therapies business) classified as held for sale following an agreement to sell to Essex Woodlands (forming Bioventus LLC), with Smith & Nephew retaining a 49% stake.
Guidance, Outlook, and Risks
- 2012 Outlook: Management expects tough market conditions to persist.
- Revenue: Sports medicine expected to slightly outperform the market; Advanced Wound Management to grow above market rate; Orthopaedic Reconstruction to grow at market rate; Orthopaedic Trauma to grow slightly below market due to royalty income reductions.
- Margins: Modest increase in trading profit margin expected in 2012.
- Strategic Priorities: Focus on "Innovate for Value," "Simplify and Improve Operating Model" (targeting $150m structural efficiency savings), and "Supplement Organic Growth through Acquisitions."
- Key Risks:
- Legal/Compliance: Ongoing FCPA investigation settled in Feb 2012 with fines/disgorgement of ~$23m and an independent monitor. Macrotextured knee revision claims remain a contingency ($17m provision).
- Market: Pricing pressure, reimbursement changes, and currency fluctuations (strong USD impacts margins).
- Operational: Supply chain disruptions and regulatory approval delays.
Investor Verification Checklist
- Legal Settlement Impact: Verify the final cost of the FCPA settlement and the impact of the independent monitor on future compliance costs.
- Clinical Therapies Disposal: Confirm the completion of the Bioventus transaction and the valuation of the retained 49% associate interest.
- Debt Maturity: Review the repayment schedule for the $306m in current borrowings (primarily the reclassified term loan due May 2012).
- Margin Recovery: Monitor Q1 and Q2 2012 results to validate the "modest margin increase" guidance amidst pricing pressures.
- Emerging Markets Growth: Assess the actual revenue contribution from China, India, Brazil, and Russia against the new strategic targets.